Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...

Patients with psoriasis aged 65 years and older achieve long-term responses to interleukin (IL)-17 and IL-23 inhibitors that are comparable with younger patients, despite experiencing slower early ...

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

《Rheumatology International》：Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple Sclerosis-like syndrome: a systematic review 【字体： 大 中 小 】 时间：2025年06月04日 ...

The global Interleukin Inhibitors Market is estimated to be valued at USD 36.78 Bn in 2025 and is expected to reach USD 85.51 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.8% from ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...

Burlingame, CA, June 17, 2025 (GLOBE NEWSWIRE) -- The global Interleukin Inhibitors Market is estimated to be valued at USD 36.78 Bn in 2025 and is e Tuesday, 02 January 2024 12:17 GMT عربي ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

The risk for major adverse cardiovascular events (MACE) among patients with psoriasis was lower with the use of apremilast or interleukin (IL)-17 inhibitors and higher with cyclosporine use when ...

For IL-17 inhibitors, the abnormal activation of Th17 cells is a key factor in a variety of inflammatory and autoimmune diseases. IL-17A and IL-17F play a pivotal role in mediating the inflammatory ...